Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.
The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as…
A new study links the consumption of ultra-processed foods to an increased risk of IBD.
A new study warns that Stelara can significantly increase the risk of heart problems and strokes among patients already at a high risk of coronary events.
Probiotics do little to help with gut health and are usually not worth the cost, according to guidelines in a new report.
The FDA has approved higher dose formulations of extended release Xeljanz, despite concerns over the risk of potentially fatal blood clots.
European regulators warn that Xeljanz should not be given to any patients at high risk of blood clots unless absolutely necessary.
The FDA is warning that Pfizer's ulcerative colitis drug, Xeljanz, could cause pulmonary embolism and deep vein thrombosis at higher doses.
European regulators have placed new restrictions on the use of Xeljanz while they continue to review potential pulmonary embolism risks.